Today's Research: Inovio Pharmaceuticals Inc., Onyx Pharmaceuticals Inc., Sequenom Inc. and Optimer Pharmaceuticals Inc.
Today's Research: Inovio Pharmaceuticals Inc., Onyx Pharmaceuticals Inc., Sequenom Inc. and Optimer Pharmaceuticals Inc. Editor Note: For more information about this release, please scroll to bottom. PR Newswire LONDON, August 29, 2013 LONDON, August 29, 2013 /PRNewswire/ -- The U.S. equity market ended higher on Wednesday, August 28, 2013. The S&P 500 advanced 0.27%, to close the day at 1,634.96. Shares of companies in the biotechnology industry also ended on a higher note, tracking gains in the broader market. The major movers included Inovio Pharmaceuticals Inc. (NYSE MKT: INO), Onyx Pharmaceuticals Inc. (NASDAQ: ONXX), Sequenom Inc. (NASDAQ: SQNM), and Optimer Pharmaceuticals Inc. (NASDAQ: OPTR). AAAResearchReports.com has completed their technical analysis on INO, ONXX, SQNM, and OPTR and these free reports are accessible by registering at: http://www.aaaresearchreports.com/register/ Shares in Inovio Pharmaceuticals Inc. finished flat on Wednesday, even as the broader market edged higher. The company's shares closed the day at $1.65 after oscillating between $1.65 and $1.72. A total of 2.29 million shares were traded, which is below the daily average volume of 7.39 million. Inovio Pharmaceuticals Inc.'s shares have gained 14.58% in the last one month and 139.09% in the last three months, compared to a decline of 3.35% and 1.51% in the S&P 500 during the respective periods. Further, the company's stock is currently trading above its 50-day and 200-day moving averages. Sign up for free technical research on INO at: http://www.AAAResearchReports.com/INO082913.pdf On Wednesday, Onyx Pharmaceuticals Inc.'s stock edged slightly higher. The stock closed the day at $123.48, which is 0.10% higher than the previous day's price of $123.36, after oscillating between $123.36 and $123.54. A total of 3.97 million shares were traded, which is above the daily average volume of 2.72 million. The company's shares have gained 5.57% in the last three trading sessions, outperforming the S&P 500 which has fallen by 1.72% during the same period. Moreover, Onyx Pharmaceuticals Inc.'s shares are trading above their 50-day and 200-day moving averages. Be sure to read our latest technical research on ONXX by registering at: http://www.AAAResearchReports.com/ONXX082913.pdf Sequenom Inc.'s stock advanced on Wednesday, reversing some of its recent losses. The company's shares oscillated between $2.91 and $3.00 before finishing the day 0.34% higher at $2.93. A total of 1.14 million shares were traded, which is below the daily average volume of 3.25 million. Sequenom Inc.'s shares have fallen by 3.30% in the last three trading sessions, compared to a loss of 1.72% in the S&P 500 during the same period. Furthermore, the company's stock is currently trading below its 50-day and 200-day moving averages. Sign up and read the complimentary report on SQNM at: http://www.AAAResearchReports.com/SQNM082913.pdf Shares in Optimer Pharmaceuticals Inc. ended higher on Wednesday, finishing at $12.53, up 0.48% from the previous closing price of $12.47. The company's shares oscillated between $12.45 and $12.58. A total of 0.48 million shares were traded, which is below the daily average volume of 1.19 million. The company's stock has declined by 0.16% in the last three trading sessions, outperforming the S&P 500 which has fallen by 1.72% during the same period. Additionally, Optimer Pharmaceuticals Inc.'s stock is trading above its 200-day moving average. The free report on OPTR can be downloaded by signing up now at: http://www.AAAResearchReports.com/OPTR082913.pdf EDITOR NOTES: 1. This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA ® charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. www.AAAresearchreports.com SOURCE AAA Research Reports Contact: Phone #: +1(646)396-9126 Contact Name: Peter F. Jones Email ID: firstname.lastname@example.org